Eleven Biotherapeutics Presents Phase 2 Clinical Data On EBI-005 For The Treatment Of Allergic Conjunctivitis At ASCRS 2015 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, will present clinical data for EBI-005, its novel, protein therapeutic which is in late-stage clinical development for dry eye disease and allergic conjunctivitis, at the American Society of Cataract and Refractive Surgery (ASCRS) 2015 Annual Meeting in San Diego, CA.

Help employers find you! Check out all the jobs and post your resume.

Back to news